The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European ...

The Most Favored Nations directive would allow drugmakers to directly sell their products to patients at a lower cost, ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

While industry groups decried the Trump administration’s new drug pricing order, analysts say it lacked details and the teeth ...